OCUL יחס מהיר Ocular Therapeutix

The GURU.Markets terminal provides a tight liquidity chart, where the current parameter is 13.42. The stability of Ocular Therapeutix (OCUL) relies on its own US-based manufacturing plant with strict sterility controls. Regular equipment calibration and zone cleanliness guarantee the uninterrupted production of drugs. Rising demand for long-acting therapies and new ophthalmological agents provide the company with operational resilience.

For Ocular Therapeutix (OCUL), whose capital expenditures on implant clinical trials create increased budget pressure, a reserve of operational resilience is critically important. By analyzing the quick ratio, an investor assesses the company's ability to settle short-term liabilities solely through cash and accounts receivable, completely excluding slow-moving inventories to identify the real solvency of the capital.